PURPOSE: The aim was to assess changes in insulin-like growth factor 1 receptor (IGF-1R) expression with immunoSPECT/CT and to study the dynamics of IGF-1R expression of human breast tumors during endocrine treatment. PROCEDURES: Mice with MCF-7 xenografts were treated with estradiol or tamoxifen, and IGF-1R expression was measured by immunohistochemistry and immunoSPECT/CT using (111)In-R1507 (anti-IGF-1R antibody). Moreover, IGF-1R expression was analyzed immunohistochemically on 22 human breast tumors, treated preoperatively with endocrine therapy. RESULTS: Estradiol resulted in an increased expression of IGF-1R, as measured by immunohistochemistry and immunoSPECT/CT. In contrast, tamoxifen resulted in a downregulation of IGF-1R, whereas this could not be measured with immunoSPECT/CT. A downregulation was also detectable in 9 out of 22 (41 %) human breast tumors after endocrine therapy. CONCLUSIONS: Anti-estrogen treatment can cause a reduction in membranous IGF-1R expression. Based on these results, a combination of anti-IGF-1R antibodies with anti-estrogen therapy might not be a rational treatment strategy.
PURPOSE: The aim was to assess changes in insulin-like growth factor 1 receptor (IGF-1R) expression with immunoSPECT/CT and to study the dynamics of IGF-1R expression of humanbreast tumors during endocrine treatment. PROCEDURES: Mice with MCF-7 xenografts were treated with estradiol or tamoxifen, and IGF-1R expression was measured by immunohistochemistry and immunoSPECT/CT using (111)In-R1507 (anti-IGF-1R antibody). Moreover, IGF-1R expression was analyzed immunohistochemically on 22 humanbreast tumors, treated preoperatively with endocrine therapy. RESULTS:Estradiol resulted in an increased expression of IGF-1R, as measured by immunohistochemistry and immunoSPECT/CT. In contrast, tamoxifen resulted in a downregulation of IGF-1R, whereas this could not be measured with immunoSPECT/CT. A downregulation was also detectable in 9 out of 22 (41 %) humanbreast tumors after endocrine therapy. CONCLUSIONS: Anti-estrogen treatment can cause a reduction in membranous IGF-1R expression. Based on these results, a combination of anti-IGF-1R antibodies with anti-estrogen therapy might not be a rational treatment strategy.
Authors: Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Addy C M van de Luijtgaarden; Janneke D M Molkenboer-Kuenen; Sandra Heskamp; Melissa H S Roeffen; Hanneke W M van Laarhoven; Peter J Houghton; Wim J G Oyen; Otto C Boerman; Winette T A van der Graaf Journal: Clin Cancer Res Date: 2011-10-28 Impact factor: 12.531
Authors: Alberto S Pappo; Shreyaskumar R Patel; John Crowley; Denise K Reinke; Klaus-Peter Kuenkele; Sant P Chawla; Guy C Toner; Robert G Maki; Paul A Meyers; Rashmi Chugh; Kristen N Ganjoo; Scott M Schuetze; Heribert Juergens; Michael G Leahy; Birgit Geoerger; Robert S Benjamin; Lee J Helman; Laurence H Baker Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: Sandra Heskamp; Otto C Boerman; Janneke D M Molkenboer-Kuenen; Wim J G Oyen; Winette T A van der Graaf; Hanneke W M van Laarhoven Journal: Int J Cancer Date: 2013-02-15 Impact factor: 7.396
Authors: Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit Journal: Nature Date: 2011-11-23 Impact factor: 49.962
Authors: Sandra Heskamp; Otto C Boerman; Janneke D M Molkenboer-Kuenen; Carla A Wauters; Luc J A Strobbe; Caroline M P W Mandigers; Peter Bult; Wim J G Oyen; Winette T A van der Graaf; Hanneke W M van Laarhoven Journal: PLoS One Date: 2015-02-13 Impact factor: 3.240